Mazdutide Phase 3 Trial Data Explained
A research team scanning ClinicalTrials.gov for next-generation obesity compounds in 2023 would have found something unusual: a Phase 3 program for a GLP-1/glucagon dual agonist running entirely at…
Blog Topic
Compounds & Peptides
Profiles of individual research compounds and peptides — mechanism, the published evidence base, and how each is studied alongside incretin therapy. Research-grade compounds referenced are sold strictly for laboratory and in-vitro use only.
Survodutide Phase 2: Liver Fat and Weight Loss Data
Survodutide: A Dual GLP-1/Glucagon Receptor Agonist A patient on a stable GLP-1 regimen for eighteen months hits a weight-loss plateau and a liver panel that still shows elevated ALT despite steady…
GLP-3 Receptor Binding Agents: What the Research Shows
When the Front Desk Starts Fielding "GLP-3" Calls A clinic running a research-support line for peptide patients started logging a new pattern in its call notes last quarter: callers asking…
GLP-1 Peptide Reconstitution and Stability Guide
Why Peptide Stability Determines Research Outcomes A compounding pharmacy processing roughly 300 reconstituted GLP-1 receptor agonist vials a month ran a routine potency check on stock that had…
Optimizing GLP-1 Peptide Sequences for Enhanced Efficacy in Weight-Loss Therapeutics: A Research Review
A compounding pharmacy client once sent over three vials of the same nominal peptide, sourced from three different suppliers, and asked why one batch showed visibly reduced potency in downstream…
Optimizing GLP-3 Peptide Stability for Effective Research: A Guide to Formulation and Handling Techniques
A contract research lab tracking a multi-week in-vitro binding assay lost an $18,000 reference-standard batch of a GLP-1 analog because a supplier shipment sat at ambient temperature for 36 hours…
Optimizing GLP-3 Peptide Reconstitution: A Practical Protocol for Minimizing Loss and Maximizing Yield
A Vial That Didn't Add Up A lab coordinator running peptide handling for a sports-performance research program pulled the quarterly inventory log and found a gap that didn't reconcile. Forty vials…
GLP-3 Peptide Stability: What the Storage and Reconstitution Data Actually Show
The Vial That Never Should Have Shipped Warm A research lab ordering a "GLP-3 peptide" for a stability comparison ran into the same problem twice in one quarter: the product arrived at ambient…
GLP-3 Peptide Candidates in Type 2 Diabetes: What In-Vitro and In-Silico Binding Data Actually Show
A research lab technician reconstitutes a lyophilized peptide vial at 9 a.m., logs the storage temperature, and by 2 p.m. is fielding a question from a PI who wants to know whether the receptor…
Optimizing GLP-3 Peptide Sequences for Enhanced Efficacy in Weight Management: Current State and Future Directions
A clinic operator running a medical weight-management practice with 300 active patients gets the same question every week from staff sourcing research materials: "the supplier calls this a GLP-3…
Optimizing GLP-3 Peptide Formulation for Enhanced Bioavailability: Excipients and Manufacturing Compared
A research lab orders three vials of the same GLP-3 peptide analog from three different suppliers to run a head-to-head stability comparison. Same nominal dose, same generic compound name on the…
Tirzepatide vs Semaglutide Stability: Storage, Reconstitution, and Potency Retention Compared
A weight-management clinic running three treatment rooms and a Friday-afternoon walk-in slot loses refrigeration over a long weekend. By Monday, forty vials of GLP-1 receptor agonist sat between…
Tirzepatide vs. Retatrutide: Peptide Structure, Receptor Targets, and Clinical Efficacy Comparison
The clinical and research communities now have two structurally related but pharmacologically distinct peptide compounds capable of producing weight reductions that approach or exceed 20% of body…
CagriSema (Cagrilintide + Semaglutide): Combination Mechanism and Phase 3 Trial Data
A weight management clinic enrolling 40 consecutive patients on semaglutide 2.4 mg (Wegovy) in 2022 saw outcomes closely tracking the 14.9% mean body weight reduction reported in STEP 1 — a…
BPC-157 and Tissue Repair on GLP-1 Therapy: Clinical Evidence and Stack Rationale
The Problem Nobody Talks About When Patients Start GLP-1 Therapy A 52-year-old male patient starts semaglutide at 0.25 mg/week. By week 12, he's down 18 pounds — but he's also reporting a nagging…